Elicera Therapeutics AB (publ) (OM: ELIC)
Health Care · Biotechnology · SE
Skr2.61
-9.06% today · -50.5% 1Y
Elicera Therapeutics AB (publ) (OM: ELIC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $20.14M and employs 3 people.
Over the last twelve months the share price has lost 50.5%, trading between 2.25 and 8.43.
Tweenvest scores Elicera Therapeutics AB (publ) across four factors: quality 26/100, value 66/100. Its strongest factor is value.
ELIC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $20.14M
- Revenue (TTM)
- $1.12M
- P/E
- —
- EPS
- -0.30
- Dividend yield
- —
- Beta (5Y)
- 0.28
- 52-week high
- Skr8.43
- 52-week low
- Skr2.25
- Avg volume (3M)
- —
- Shares outstanding
- 66.74M
- Employees
- 3
- Next earnings
- —
About Elicera Therapeutics AB (publ)
Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several drug candidates, including ELC-100, which is currently undergoing Phase I/II trials for neuroendocrine tumors. The company is also advancing ELC-201 and ELC-401 through preclinical development, with ELC-401 specifically targeting glioblastoma multiforme (a form of brain tumor). Furthermore, Elicera is developing ELC-301, a CAR T-cell therapy intended for the treatment of Non-Hodgkin's B-cell lymphoma. A cornerstone of their work is the iTANK technology platform, engineered to enhance the efficacy of their CAR T-cell therapies and stimulate killer T-cells to attack cancerous cells.
- Founded
- 2014
- Listed since
- Jun 11, 2021
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.62 | -1.69% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.